FAA Medical After SSRI or Antidepressant Use: What the Evaluation Requires (2026)

If you are a pilot or pilot applicant with a current or past SSRI prescription, the FAA has a defined pathway for medical certification. The process depends on whether you are still taking the medication, how long ago you stopped, and which medication was prescribed.

This article covers the SSRI pathway specifically. If your history involves anxiety or depression but no SSRI use, read the FAA Anxiety & Depression Fast Track overview instead. If your history involves ADHD, that follows a separate process called the ADHD Fast Track.

Which SSRIs does the FAA accept?

The FAA allows medical certification while taking one of four approved SSRIs:

• fluoxetine (Prozac)

• sertraline (Zoloft)

• citalopram (Celexa)

• escitalopram (Lexapro)

Three additional classes are accepted under the broader anxiety and depression pathway:

• SNRIs: desvenlafaxine (Pristiq), duloxetine (Cymbalta), venlafaxine (Effexor)

• NDRIs: bupropion sustained or extended release (Wellbutrin SR/XL)

• Selective Serotonin Reuptake Inhibitor/ 5-HT1A Receptor Partial Agonist: vilazodone (Viibryd)

If you are taking or have taken a medication not on this list, the FAA will not process your case through the standard SSRI pathway. Medications such as paroxetine (Paxil), fluvoxamine (Luvox), and all benzodiazepines, antipsychotics, mood stabilizers, and lithium are not accepted.

Three scenarios and what each requires

Scenario 1: Currently taking an approved SSRI

You can receive medical certification to fly while taking an approved SSRI, but the FAA requires a structured evaluation before certification. The process includes:

• A clinical evaluation by an AME or a qualified mental health professional confirming that the condition is stable and that the medication is effective without side effects that impair cockpit performance.

• Documentation of at least 3 months of stable treatment on the current medication and dose.

• A CogScreen-AE, administered by a qualified examiner, to verify that the SSRI is not impairing attention, processing speed, or working memory. If the results show weaknesses, additional testing will be performed.

• A letter from the prescribing physician confirming diagnosis, medication history, dosing, treatment response, and absence of side effects.

• Follow-up CogScreen-AE testing if clinically indicated or specified in the authorization letter.

The CogScreen-AE is a critical step. It is the FAA's standard cognitive screening tool for pilots on psychoactive medication. It measures the specific cognitive skills required for flight: divided attention, processing speed, working memory, and psychomotor coordination. The test must be administered in person by an examiner who holds the CogScreen-AE Pro qualification.

Scenario 2: Recently stopped an approved SSRI (within 2 years)

If you have discontinued an approved SSRI within the past two years, the FAA treats the case differently depending on the reason for discontinuation and the time elapsed.

• If you stopped within the past 60 days, you must wait at least 60 days after the last dose before applying for medical certification. The FAA requires this washout period to confirm that withdrawal effects have resolved.

• If you stopped between 60 days and 2 years ago, you may qualify under the anxiety and depression pathway if the underlying condition has resolved and you have been stable off medication.

• Documentation required: prescriber letter confirming the reason for discontinuation, dates of use, current clinical status, and confirmation that no other psychoactive medications are being used.

  
  

Scenario 3: Stopped an approved SSRI more than 2 years ago

If more than two years have passed since your last SSRI use and the underlying condition has resolved, the process is simpler. In many cases, the AME can issue certification without a full neuropsychological evaluation, provided the documentation is complete and the history is straightforward.

You will still need:

• A letter from the treating clinician confirming diagnosis, dates of treatment, reason for discontinuation, and current clinical status.

• Pharmacy records covering the period of use and confirming no fills after the reported stop date.

• A personal statement explaining the circumstances.

If the condition has recurred, required treatment changes, or involved any disqualifying history (hospitalization, suicidal behavior, substance misuse), the AME cannot clear the case and will defer to Oklahoma City.

What triggers a deferral

The AME must defer your application if any of the following apply:

• You are taking or have taken a non-approved psychoactive medication.

• You required more than one antidepressant at the same time.

• The underlying diagnosis is major depressive disorder, bipolar disorder, psychosis, or another condition outside the anxiety/depression pathway.

• There is a history of psychiatric hospitalization, suicidal behavior, or involuntary evaluation.

• Treatment involved ECT, TMS, ketamine, or psychedelics.

• The CogScreen-AE results show impairment.

Note that a deferral does not mean denial. It means the FAA will review the case in Oklahoma City and may request additional documentation or a full neuropsychological evaluation by a HIMS-certified neuropsychologist.

The CogScreen-AE and why it matters

The CogScreen-AE is a computerized screening tool developed for the FAA that measures cognitive function under conditions that approximate the cognitive demands of flight operations. The FAA uses it to verify that the SSRI is not causing cognitive side effects that could impair safety. The test is administered in a single session. Results are scored against FAA normative data and interpreted in the context of the full clinical evaluation.

What to do before your AME appointment

Arriving unprepared is the most common reason pilots get deferred when they should have qualified.

1. Confirm your medication is on the FAA's approved list before scheduling.

2. Confirm that your AME is familiar with the Anxiety and Depression Fast Track pathway.

3. Obtain a letter from your prescriber covering: diagnosis, treatment dates, current medication and dose, treatment response, side effects (or absence of), and current clinical status.

4. Pull pharmacy records covering the past 2 to 4 years.

5. If you are currently on an SSRI, verify that you have been on a stable dose for at least 6 months.

6. Schedule a CogScreen-AE with a qualified examiner before or concurrent with your AME visit. Confirm this in advance.

7. Prepare a personal statement describing the circumstances of your diagnosis and treatment.

   
   

When a full neuropsychological evaluation is required

If the AME defers your case, the FAA may request a full psychological or neuropsychological evaluation. This is a more extensive process than the CogScreen alone. It includes a clinical interview, review of the complete FAA medical file, the CogScreen-AE Pro, and a comprehensive neuropsychological test battery. The report is written to FAA documentation standards and addresses every concern identified in the deferral letter.

If you have received a deferral letter requiring a full evaluation, schedule a 15-minute consultation.

Related resources

• FAA Anxiety & Depression Fast Track

• FAA ADHD Fast Track: The #1 Mistake to Avoid

• Planning After the FAA Requests a Neuropsychological Evaluation

• FAA Neuropsychological Evaluations

Written by Jason Olin, PhD, Licensed Clinical Psychologist and Neuropsychologist.

Dr. Olin provides psychological and neuropsychological evaluations for FAA medical certification, including CogScreen-AE Pro administration. He is one of approximately 130 HIMS-certified neuropsychologists nationally and the only one listed for Orange County on the FAA neuropsychologist list. Licensed in California, New York, Arizona, Florida, and Idaho. Telehealth available in 42 PSYPACT states.